| Phase 15 trials |
|
Phase 1
|
NCT06442761 |
Nov 2024 → Jan 2028 expected |
sickle cell disease |
St. Jude Children's Research Hospital |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06547112 |
Oct 2024 → Jul 2025 |
plasma cell myeloma |
Washington University School of Medicine |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05618301 |
Jul 2023 → Jun 2025 |
sickle cell disease |
Washington University School of Medicine |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05293171 |
Jun 2021 → Jun 2022 |
— |
BioLineRx, Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02073019 |
Aug 2014 → Jul 2015 |
hemopoietic proliferation |
BioLineRx, Ltd. |
Completed
|
No outcome recorded
|
| Phase 1/25 trials |
|
Phase 1/2
|
NCT03154827 |
Jan 2018 → Apr 2020 |
acute myeloid leukemia |
BioLineRx, Ltd. |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT03281369 |
Oct 2017 → Oct 2025 |
digestive system carcinoma |
Hoffmann-La Roche |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT03193190 |
Jul 2017 → Feb 2025 |
pancreatic adenocarcinoma |
Hoffmann-La Roche |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT02115672 |
Nov 2014 → Nov 2016 |
chronic myeloid leukemia |
Sheba Medical Center |
Withdrawn
|
No outcome recorded
|
|
Phase 1/2
|
NCT01010880 |
Oct 2008 → Jul 2010 |
plasma cell myeloma |
Biokine Therapeutics Ltd |
Completed
|
No outcome recorded
|
| Phase 29 trials |
|
Phase 2
|
NCT07392970 |
Jul 2026 → Aug 2028 expected |
acute myeloid leukemia |
Washington University School of Medicine |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04543071 |
Nov 2020 → Jun 2028 expected |
pancreatic adenocarcinoma |
Gulam Manji |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT02763384 |
Dec 2016 → Feb 2022 |
T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma |
Washington University School of Medicine |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT02907099 |
Dec 2016 → Oct 2023 |
pancreatic adenocarcinoma |
M.D. Anderson Cancer Center |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02826486 |
Sep 2016 → Sep 2022 |
pancreatic adenocarcinoma |
BioLineRx, Ltd. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02639559 |
Mar 2016 → Apr 2018 |
Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia +2 |
Washington University School of Medicine |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02462252 |
Oct 2015 → Nov 2020 |
aplastic anemia, myelodysplastic syndrome |
BioLineRx, Ltd. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02502968 |
Sep 2015 → Jul 2018 |
acute myeloid leukemia |
Dr. Petra Tschanter |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT01838395 |
Apr 2013 → Mar 2016 |
acute myeloid leukemia |
BioLineRx, Ltd. |
Completed
|
No outcome recorded
|
| Phase 32 trials |
|
Phase 3
|
NCT06514508 |
Dec 2025 → Dec 2026 expected |
plasma cell myeloma |
Guangzhou Gloria Biosciences Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT03246529 |
Mar 2018 → Dec 2020 overdue |
plasma cell myeloma |
BioLineRx, Ltd. |
Active not recruiting
|
No outcome recorded
|
| Phase 41 trial |
|
Phase 4
|
NCT07101445 |
Sep 2025 → Dec 2026 expected |
plasma cell myeloma |
Emory University |
Recruiting
|
No outcome recorded
|